CLINICAL TRIALS PROFILE FOR INNOPRAN XL

All Clinical Trials for INNOPRAN XL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00934947 ↗	Burn Healing and Analgesia With Propranolol	Completed	University of North Carolina, Chapel Hill	Phase 2	2009-07-01	The purpose of this study is to investigate the ability of propranolol to decrease pain and improve recovery in burn patients with a common genotype.
NCT01007084 ↗	TRAUMA HELP: Healing and Analgesia With Propranolol	Withdrawn	University of North Carolina, Chapel Hill	Phase 2	2009-10-01	The purpose of this study is to determine whether propranolol can decrease pain symptoms in a common subset of patients admitted to a trauma center after injury.
NCT01222091 ↗	Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids	Completed	Stanford University	Phase 2	2009-02-01	This research study explores whether a beta-blocker (propranolol) can prevent a person from becoming more sensitive to pain after administration of an opioid (remifentanil). Beta blockers inhibit the sympathetic (fight or flight) response and are often used to treat angina and high blood pressure. In a previous study in human volunteers, the investigators demonstrated an increased sensitivity to pain after a 60-minute infusion of the opioid remifentanil. The goal of this study is to identify a possible inhibitor of this phenomenon.
NCT02871349 ↗	Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response	Completed	United States Department of Defense	Early Phase 1	2016-08-01	The purpose of this study is to find out how the brain of people with autism is affected by Propranolol. Propranolol is not FDA approved for the treatment of autism. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure This research is being done because there are currently no drug treatment options for language impairments and social difficulties often experienced by people with autism.
NCT02871349 ↗	Trial of Propranolol in Children and Youth With Autism Spectrum Disorder and Predictors of Response	Completed	University of Missouri-Columbia	Early Phase 1	2016-08-01	The purpose of this study is to find out how the brain of people with autism is affected by Propranolol. Propranolol is not FDA approved for the treatment of autism. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure This research is being done because there are currently no drug treatment options for language impairments and social difficulties often experienced by people with autism.

Clinical Trial Conditions for INNOPRAN XL

Condition Name

Condition Name for INNOPRAN XL
Intervention	Trials
Pain	1
Trauma	1
Autism Spectrum Disorder	1
Burns	1

Condition MeSH

Condition MeSH for INNOPRAN XL
Intervention	Trials
Disease	1
Child Development Disorders, Pervasive	1
Autistic Disorder	1
Autism Spectrum Disorder	1

Clinical Trial Locations for INNOPRAN XL

Trials by Country

Trials by Country for INNOPRAN XL
Location	Trials
United States	6

Trials by US State

Trials by US State for INNOPRAN XL
Location	Trials
North Carolina	2
Missouri	1
California	1
Pennsylvania	1
District of Columbia	1

Clinical Trial Progress for INNOPRAN XL

Clinical Trial Phase

Clinical Trial Phase for INNOPRAN XL
Clinical Trial Phase	Trials
Phase 2	3
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for INNOPRAN XL
Clinical Trial Phase	Trials
Completed	3
Withdrawn	1

Clinical Trial Sponsors for INNOPRAN XL

Sponsor Name

Sponsor Name for INNOPRAN XL
Sponsor	Trials
University of North Carolina, Chapel Hill	2
Stanford University	1
United States Department of Defense	1

Sponsor Type

Sponsor Type for INNOPRAN XL
Sponsor	Trials
Other	4
U.S. Fed	1